Repatha dosing schedule
Searched over 200M research papers
Summary
4 papers analyzed
These studies suggest that Evolocumab (Repatha) is an effective treatment for lowering LDL-C levels in patients with various forms of hypercholesterolemia, especially when statins are insufficient or not tolerated, although its long-term efficacy and safety remain to be fully established.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Repatha Dosing Schedule: An Overview
Introduction to Repatha (Evolocumab)
Repatha, also known by its generic name evolocumab, is a monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9). This medication is primarily used to lower low-density lipoprotein cholesterol (LDL-C) levels in patients with hyperlipidemia, including those with familial hypercholesterolemia .
Standard Dosing Schedule
Biweekly Dosing
One of the standard dosing schedules for Repatha involves administering 140 mg subcutaneously every two weeks. This regimen has been shown to significantly reduce LDL-C levels in various patient populations, including those with primary hypercholesterolemia, mixed dyslipidemia, and both heterozygous and homozygous familial hypercholesterolemia .
Monthly Dosing
Alternatively, Repatha can be administered at a dosage of 420 mg once monthly. This dosing schedule offers a similar efficacy in lowering LDL-C levels and provides flexibility for patients who may prefer less frequent injections .
Efficacy and Safety
LDL-C Reduction
Clinical trials have demonstrated that Repatha, whether administered biweekly or monthly, can reduce LDL-C levels by approximately 50-60% from baseline when added to statin therapy or used as monotherapy in statin-intolerant patients . This significant reduction in LDL-C is consistent across various patient groups, including those with high cardiovascular risk.
Long-term Efficacy and Safety
The long-term efficacy and safety of Repatha have been evaluated in controlled trials lasting from 12 to 76 weeks. These studies indicate that Repatha is well-tolerated and maintains its efficacy over extended periods . However, the long-term impact on cardiovascular outcomes remains to be fully established.
Conclusion
Repatha offers a flexible and effective treatment option for lowering LDL-C levels in patients with hyperlipidemia. The biweekly 140 mg and monthly 420 mg dosing schedules provide significant reductions in LDL-C, making it a valuable addition to lipid-lowering therapies, especially for patients who are unable to achieve their LDL-C goals with statins alone or who are statin-intolerant.
Sources and full results
Most relevant research papers on this topic
